source
- J&J and AbbVie present early trispecific antibody data for multiple myeloma at ASH meetingAt the American Society of Hematology (ASH) meeting, Johnson & Johnson and AbbVie are slated to share early clinical data on trispecific antibodies targeting multiple myeloma. These next‑generation…
- T-Therapeutics secures $133 million Series B to advance bispecific cancer and autoimmune drugsT-Therapeutics, a UK-based biotech focused on T-cell engager technology, announced a $133 million Series B financing. The capital will be used to generate proof-of-concept data for its lead bispec…